How We Think
Complex life sciences and medtech investments rarely fail because no one produced enough analysis. They fail when an assumption that looked reasonable in isolation does not hold up in the real world.
SVI brings the perspective of someone who has made these decisions from inside the business: leading strategy, R&D, corporate development, commercial organizations, partnerships, and P&Ls across pharmaceuticals, biotech, diagnostics, medical devices, and radiopharmaceuticals.
That experience changes how an investment is viewed.
Clinical, regulatory, commercial, reimbursement, manufacturing, organizational, and financial questions do not operate independently.
A finding that appears manageable within one function can become material when its consequences are understood across the business.
SVI looks at the investment as a whole, not as a collection of separate diligence reports.
An asset does not create value by itself.
Leadership, organizational capability, capital, operating infrastructure, relationships, and execution all influence what an owner can realistically achieve.
The relevant question is therefore not only whether an asset is attractive. It is whether the investment case is achievable in the environment that has to deliver it.
Diligence can generate an enormous amount of information without materially changing the investment conclusion.
Senior judgment is knowing what deserves attention, what is consequential, and what is simply interesting.
The objective is not completeness for its own sake. It is clarity on the issues capable of changing the decision.
Markets can look large. Clinical results can look compelling. Forecasts can appear precise.
The investment still has to work in the environment in which patients, physicians, hospitals, payers, regulators, manufacturers, competitors, and management actually operate.
SVI brings those realities into the investment discussion before they become post-investment surprises.
A transaction does not create the value assumed in the investment case.
That value still has to be earned through execution.
The strongest diligence therefore leaves investors with more than a view on whether to proceed. It creates a clearer understanding of where value can be created, where it can be lost, and what deserves management attention after the decision is made.
SVI is designed around senior judgment rather than a large delivery hierarchy.
Bob Basore leads the engagement, integrates the findings, and owns the conclusion. Experienced specialists are brought in where additional depth is required, while responsibility for the overall investment perspective remains with SVI.
The objective is straightforward: a better-informed investment decision and a clearer view of what has to happen for the thesis to become value.